JPMorgan analyst James Gordon lowered the firm’s price target on Genmab to DKK 3,400 from DKK 3,600 and keeps an Overweight rating on the shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GMAB:
- Transactions in connection with share buy-back program
- Genmab price target lowered to $46 from $51 at H.C. Wainwright
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab